#Germany #gene therapy #Cell Therapy #Minaris Advanced #Taufkirchen

Minaris Advanced Therapies Expands Global Footprint with New GMP Facility

MUNICH, August 4, 2025 – Minaris Advanced Therapies, a leading global organization in contract development, manufacturing, and testing, has officially opened its new state-of-the-art GMP facility located in Taufkirchen, Germany. This significant milestone further strengthens Minaris' global manufacturing capabilities and solidifies its reputation as a trusted partner for cutting-edge therapy development from concept to commercialization.

The new facility boasts top-tier infrastructure and operational flexibility designed to meet the increasing European demand for advanced therapies. With the existing team already based in the vicinity, the transition to the new site ensures a wealth of clinical and commercial manufacturing expertise along with process development and analytical capabilities. Strategically located just minutes away from Munich International Airport, the facility provides a logistical advantage that will benefit clients across Europe and worldwide.

Feature Highlights of the New Facility

The Taufkirchen facility is equipped with modern amenities, including:

• - Six B/A grade clean rooms for aseptic manufacturing, ensuring a sterile environment for sensitive processes.
• - A C-grade clean room designed specifically for bioreactors and closed systems, which can be converted to A/B grade when required.
• - Customizable clean room configurations and 224 square meters (2,411 square feet) of expansion space, allowing for scalability in operations.
• - HVAC systems with independent control for each clean room that reduces downtime and enables parallel production activities.
• - Dedicated laboratories for process development and quality control to uphold rigorous safety standards.
• - Advanced cryopreservation and storage facilities to maintain the integrity of sensitive materials.
• - Enhanced alarm and security systems ensuring comprehensive oversight.

Leadership Quotes

Dr. Orla Cloak, CEO of Minaris Advanced Therapies, remarked on the significance of this opening: "The launch of our new facility marks an important milestone in our mission to accelerate the global development and manufacturing of transformative cell and gene therapies. Our expanded presence in Europe enables us to swiftly and effectively meet our clients' needs with high-quality and scalable solutions."

Iain Baird, the chairman of the board, also shared his insights, stating, "This facility embodies our shared vision for the future of scalable and integrated cell and gene therapy manufacturing on a global scale. It showcases the dedication of our German team and the strength of the Minaris-Altaris collaboration in delivering long-term value to clients and patients around the world."

The grand opening of the new facility was celebrated on July 31, marking a new chapter for Minaris as it continues to pursue excellence in the field of biopharmaceutical manufacturing.

About Minaris Advanced Therapies

Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) that specializes in cell and gene therapies. Headquartered in Philadelphia, Pennsylvania, Minaris operates over 650,000 square feet of facilities across the United States, Europe, and Asia. The organization has manufactured and released over 7,500 GMP-compliant batches, providing essential support to therapy developers at various stages, from early development to clinical trials and commercial production.

Minaris is part of the Altaris portfolio, an investment firm focused exclusively on acquiring and developing health sector companies. Since its inception in 2003, Altaris has invested in over 50 companies across various healthcare sub-sectors, aiming to generate attractive financial returns while enhancing the healthcare system. Altaris is headquartered in New York and manages $10 billion in equity capital.

For more information, please visit www.altariscap.com.